Efficacy and safety of dostarlimab in UK-specific patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) or DNA polymerase epsilon, catalytic subunit (POLε)-mutated solid tumours in the GARNET study

被引：0
|
作者：
Samuel, L.
Miller, R.
Ross, P.
Arkenau, T. [1 ]
Antony, G. [2 ]
Veneris, J.
Rule, J. [2 ]
Starling, N. [3 ]
机构：
[1] Sarah Cannon Res Inst, London, England
[2] GlaxoSmithKline, London, England
[3] Royal Marsden, London, England
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
基金：
芬兰科学院;
关键词：
D O I：
10.1016/j.annonc.2023.04.220
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-164
引用
收藏
页码：S73 / S74
页数：2
相关论文
共 50 条
  • [21] Progression-free survival (PFS) and overall survival (OS) in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC) treated with dostarlimab in the GARNET study
    Tinker, A. V.
    Pothuri, B.
    Gilbert, L.
    Sabatier, R.
    Brown, J.
    Ghamande, S.
    Mathews, C.
    O'Malley, D.
    Boni, V.
    Gravina, A.
    Banerjee, S.
    Miller, R.
    Pikiel, J.
    Mirza, M. R.
    Duan, T.
    Antony, G.
    Zildjian, S.
    Zografos, E.
    Veneris, J.
    Oaknin, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S798 - S799
  • [22] FREQUENCY OF AND TESTING PATTERNS FOR MICROSATELLITE INSTABILITY HIGH (MSI-H) AND DEFICIENT MISMATCH REPAIR (DMMR) AMONG SOLID TUMORS IN A US COMMUNITY ONCOLOGY SETTING
    Chase, M.
    Vasudevan, A.
    Amonkar, M.
    Myer, N.
    Wang, T.
    Prabhu, V
    Turzhitsky, V
    Spira, A.
    VALUE IN HEALTH, 2022, 25 (07) : S452 - S452
  • [23] Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) stage IV colorectal cancer (CRC)
    Andre, Thierry
    Sposetti, Caterina
    Gumus, Mahmut
    Ahn, Joong Bae
    Wyrwicz, Lucjan
    Kwiatkowski, Mariusz
    Kim, Jong Gwang
    Yalcin, Suayib
    Sendur, Mehmet A. N.
    Odeleye-Ajakaye, Amos
    Leconte, Pierre
    Fogelman, David R.
    Kim, Tae Won
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H)
    Berton-Rigaud, D.
    Pautier, P.
    Lorusso, D.
    Gennigens, C.
    Gladieff, L.
    Kryzhanivska, A.
    Bowman, J.
    Tian, C.
    Cornfeld, M.
    Van Gorp, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S517 - S517
  • [25] Neoadjuvant nivolumab plus ipilimumab in microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) rectal tumors: ECOG-ACRIN EA2201
    Ciombor, K. K.
    Hong, S.
    Eng, C.
    Yao, X.
    You, N.
    Das, P.
    Chakravarthy, A.
    O'Dwyer, P. J.
    ANNALS OF ONCOLOGY, 2024, 35 : S104 - S104
  • [26] An unusual case of microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) diffuse large B-cell lymphoma revealed by targeted gene sequencing
    Han, Bogyeong
    Kim, Sehui
    Koh, Jiwon
    Bae, Jeong Mo
    Yun, Hongseok
    Jeon, Yoon Kyung
    JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, 2022, 56 (02) : 92 - 96
  • [27] Initial findings from the DREAM-GI national database: Assessing the efficacy and safety of neoadjuvant immunotherapy (NIT) in patients with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) gastrointestinal (GI) cancer.
    Chakrabarti, Sakti
    Selfridge, J. Eva
    Parish, Marie
    Bajor, David L.
    Ruggeri, Antony
    Tolay, Sameer
    Conces, Madison
    Lumish, Melissa Amy
    Mohamed, Amr
    Mahipal, Amit
    Shreenivas, Aditya V.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 736 - 736
  • [28] Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability-high tumors: A combined analysis of two cohorts in the GARNET study.
    Berton, Dominique
    Banerjee, Susana N.
    Curigliano, Giuseppe
    Cresta, Sara
    Arkenau, Hendrik-Tobias
    Abdeddaim, Cyril
    Kristeleit, Rebecca Sophie
    Redondo, Andres
    Leath, Charles A.
    Torres, Antonio Anton
    Guo, Wei
    Im, Ellie
    Andre, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial
    Bi, Feng
    Dong, Jian
    Jin, Chuan
    Niu, Zuoxing
    Yang, Wenhui
    He, Yifu
    Yu, Dajun
    Sun, Meili
    Wang, Teng
    Yin, Xianli
    Zhang, Ruixing
    Chen, Kehe
    Wang, Keming
    Wang, Zhiwu
    Li, Wei
    Zhang, Zhongtao
    Zhang, Hangyu
    Guo, Qunyi
    Wang, Xin
    Han, Lei
    Zhang, Xizhi
    Shen, Wei
    Zhang, Liangming
    Ying, Jieer
    Wu, Miao
    Hu, Weiguo
    Li, Zeng
    Li, Xiaofen
    Feng, Wenlei
    Zhang, Baihui
    Li, Lingyan
    Kang, Xiaoyan
    Guo, Weijian
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [30] Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors
    Li, Jian
    Xu, Ye
    Zang, Aimin
    Gao, Yunong
    Gao, Quanli
    Zhang, Yanqiao
    Wang, Dong
    Xu, Jianming
    Yuan, Ying
    Jiang, Haiping
    Ying, Jieer
    Shi, Chunmei
    Deng, Yanhong
    Wang, Jing
    Liu, Tianshu
    Huang, Yi
    Xu, Yaling
    Wang, Yidi
    Fei, Cong
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
12345